Abstract: The present invention relates to compounds, compositions, and methods, for treating viral infections. In particular, entry inhibitor compounds are disclosed for treatment of coronavirus infections, including SARS-COV-1 and SARS-COV-2 infections. The compounds bind to the interface of a SARS-COV-2 spike protein receptor binding domain (RBD) and a host cell ACE-2 receptor. The entry inhibitor compounds show antiviral activity, favorable kinetics, and temporally act at the entry of SARS-COV-2 infection. In embodiments, the compounds are used as medicaments for the inhibition of viral replication including SARS-COV-1 and/or SARS-COV-2 replication, for the treatment or prophylaxis of viral infections including SARS-COV-1 and SARS-COV-2 infections, and/or for the treatment or prophylaxis of an illness due to SARS-COV-1 and SARS-COV-2 infections.

Abstract: An aspect provides a method, including receiving an indication that a tag associated with a real time location system has been detected at a pre-determined location, the detected tag being associated with a patient in a hospital; and assigning a status of the patient based on detection of the tag; and updating a bed availability indication based on detection of the tag. Other aspects are described and claimed.

Abstract: An aspect provides a method, including receiving an indication that a tag associated with a real time location system has been detected at a pre-determined location, the detected tag being associated with a patient in a hospital; and assigning a status of the patient based on detection of the tag; and updating a bed availability indication based on detection of the tag. Other aspects are described and claimed.